| |  | | Be it enacted by the People of the State of Maine as follows: | 
 | 
 
 
 |  | |  | Sec. 1.  22 MRSA §3174-DD is enacted to read: | 
 | 
 
 
 |  | | §3174-DD.__Drug Utilization Review Committee | 
 | 
 
 
 |  | |  | 1.__Authority.__The department has the authority to |  | determine which prescription and over-the-counter drugs are |  | subject to prior authorization and coverage under the |  | MaineCare program. | 
 | 
 
 
 |  | |  | 2.__Drug Utilization Review Committee.__In order to make |  | determinations regarding which prescription and over-the- |  | counter drugs are subject to prior authorization, the Drug |  | Utilization Review Committee, referred to in this section as |  | "the committee," is established. | 
 | 
 
 
 |  | | A.__The committee is composed of an equal number of |  | actively practicing physicians and actively practicing |  | pharmacists, totaling not fewer than 6 individuals.__The |  | department shall appoint the members of the committee and |  | establish their terms. | 
 | 
 
 
 |  | | B.__Public notice of the date, time and location of all |  | meetings of the committee must be made in accordance with |  | Title 1, section 406 at least 7 days in advance of the |  | meeting.__This notice must also include a list of all |  | drugs to be considered for prior authorization at that |  | meeting.__The meetings must be considered public |  | proceedings, for purposes of Title 1, chapter 13.__Members |  | of the public, including health care providers and drug |  | manufacturers, who are physically present at committee |  | meetings must be granted reasonable opportunity to address |  | the committee prior to any vote. | 
 | 
 
 
 |  | | C.__At the conclusion of a meeting pursuant to paragraph |  | B, committee members shall record their vote for each drug |  | on a form to be supplied at each meeting.__After adding or |  | deleting a drug from the list of drugs that require prior |  | authorization, the committee shall issue written findings |  | setting forth the evidentiary basis for its decision.__ |  | These findings must address, without limitation, all |  | relevant clinical data, as well as the likelihood that |  | subjecting a drug to prior authorization will cause |  | adverse medical results or affect patients' access to all |  | medically necessary outpatient drugs.__A vote of at least |  | 2/3 of the committee members present is required to add or |  | delete a drug from the list of drugs that require prior |  | authorization. | 
 | 
 
 
 
 |